Autopsy report · NCT03209232
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
Cause of deathSlow enrollment
“Difficulty to recruit patients and as high dose infliximab for severe UC is now the rule rather than the exception”
Life of this trial
- Registered 9 months before it started.
- Ran for about 3 years 5 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Schneider Children's Medical Center, Israel
- Sponsor type
- University, hospital or other
- Conditions
- Ulcerative Colitis
- Interventions
- Infliximab
- Participants
- 10
- Sites
- 1
- Countries
- Israel
Trials that died the same way
- Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
“due to the difficulty to enroll suitable patients” - A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
“Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage” - Effects of Physical Treatment on Postural Stability in Benign Paroxysmal Positional Vertigo (BPPV) Patients
“major difficulties recruiting patients” - Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
“difficult to recruit patients” - Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer
“Too narrow inclusion criteria. Impossible to recruit patients.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.